symbol RCUS
会社名 Arcus Biosciences Inc (ARCUS BIOSCIENCS)
業種 医薬品   医療関連(Health Care)
概要 Arcus Biosciences Inc. is a United States-based clinical-stage biotechnology company. The Company is focused on the discovery and development of cancer immunotherapy. Its pipeline includes AB928 AB680 AB122 and AB154. AB928 is a potent and selective dual antagonist of the adenosine receptors known as A2aR and A2bR.It is in the Phase-I clinical trial. AB680 is a potent and selective inhibitor of CD73 and is in the pre-clinical stage of development. AB122 is an anti-PD-1 antibody and is in the Phase-I dose-escalation trial. AB154 is a humanized anti-TIGIT antibody.  ア―カス・バイオサイエンシズは米国のバイオ医薬品企業。臨床段階で、がんに対し創造的で革新的な免疫治療の開発に従事する。同社は、科学的デ―タによって十分に特徴付けられた生物学的経路を標的とし、がんに対する免疫応答の調節の重要性に焦点を当てる。本社所在地はカリフォルニア州ヘイワ―ド。  
本社所在地 3928 Point Eden Way Hayward CA 94545 USA
代表者氏名 Juan Carlos Jaen
代表者役職名 President Co-Founder
電話番号 +1 650-489-9000
設立年月日 42095
市場名 NYSE(ニューヨーク証券取引所)
従業員数 108人
EBITDA (百万ドル) -51.19500
時価総額 (百万ドル) 557.12770
売上高 (百万ドル) 8.35300
企業価値(EV) (百万ドル) 300.58370
当期純利益 (百万ドル) -49.59400
決算概要 BRIEF: For the fiscal year ended 31 December 2018 Arcus Biosciences Inc revenues increased from $1.4M to $8.4M. Net loss decreased 7% to $49.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest and other income net increase from $359K to $4.9M (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.27 to -$1.43.


 関連キーワード  (医薬品 米国株 ARCUS BIOSCIENCS RCUS )

 twitter  (公式ツイッターやCEOツイッターなど)